Biogen Inc. Common Stock (BIIB)

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)

Market region: US

Address: 225 Binney Street, Cambridge, MA, 02142

Market capitalization

37.49 billion USD (37,490,164,957 USD)

Listing date

09/17/1991

Weighted shares outstanding

147,820,223

Share class shares outstanding

147,753,998

https://www.biogen.com